Halting the Epidemic of Addiction and Loss Act of 2025

This bill requires that, when the Department of Health and Human Services (HHS) issues new regulations or guidance on grant programs addressing opioid use disorders, references to an opioid overdose reversal drug (e.g., naloxone) must broadly include any opioid overdose reversal drug approved by the Food and Drug Administration. Within one year after the bill’s enactment, HHS must update all references accordingly in regulations or guidance issued prior to the bill’s enactment that are applicable to State Opioid Response Grants, Tribal Opioid Response Grants, or certain other grants relating to substance use disorder prevention.